Skip to main
GDRX
GDRX logo

GoodRx Holdings (GDRX) Stock Forecast & Price Target

GoodRx Holdings (GDRX) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 21%
Buy 33%
Hold 42%
Sell 4%
Strong Sell 0%

Bulls say

GoodRx Holdings Inc. has revised its revenue growth expectations for 2024 to a mid-single-digit percentage (MSD%), reflecting an improvement from its prior range of approximately 2.1-5.4%, indicating a potential for stronger performance than consensus estimates. This optimistic outlook is supported by a superior margin profile and increased utilization from seasonal factors and strategic initiatives such as retailer direct contracting. Furthermore, the company's 4Q23 revenue exceeded consensus by 2.7%, reinforcing the positive trajectory and potential for re-accelerated growth in both its membership and manufacturer solutions business.

Bears say

GoodRx Holdings Inc. faces multiple headwinds, including a significantly reduced revenue growth outlook for 2024 projected at only 2-5%, compounded by ongoing issues with declining volumes at Kroger and uncertainty surrounding the company's revenue guidance, which was approximately 6.5% below consensus estimates. Additionally, the company's growth may be adversely affected by the delayed launch of important programs, such as the ESI program and the Caremark program, which could limit its competitive positioning in the market. Furthermore, changes in the regulatory environment and the potential for increased competition from employers offering free generics threaten GoodRx's ability to sustain its revenue and profitability moving forward.

GoodRx Holdings (GDRX) has been analyzed by 24 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 33% recommend Buy, 42% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GoodRx Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GoodRx Holdings (GDRX) Forecast

Analysts have given GoodRx Holdings (GDRX) a Buy based on their latest research and market trends.

According to 24 analysts, GoodRx Holdings (GDRX) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GoodRx Holdings (GDRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.